Research graph
References from Proteostasis (in)action: the role of co-pathologies in neurodegenerative disease. Local targets link to admitted publications; unresolved targets remain external evidence.
Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases
10.1038/s41593-018-0235-9 · 2018 · External reference
Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: examples of amyloidopathies, tauopathies and synucleinopathies
10.1016/j.pneurobio.2015.07.003 · 2017 · External reference
Aggregation of disordered proteins associated with neurodegeneration
10.3390/ijms24043380 · 2023 · External reference
Alzheimer disease
10.1038/s41572-021-00269-y · 2021 · External reference
Parkinson's disease
10.1056/nejmra2401857 · 2024 · External reference
Amyotrophic lateral sclerosis
10.1016/s0140-6736(22)01272-7 · 2022 · External reference
Crucial role of protein oligomerization in the pathogenesis of Alzheimer's and Parkinson's diseases
10.1111/febs.14587 · 2018 · External reference
Large-scale visualization of alpha-synuclein oligomers in Parkinson's disease brain tissue
10.1038/s41551-025-01496-4 · 2025 · External reference
Walking the tightrope: proteostasis and neurodegenerative disease
10.1111/jnc.13575 · 2016 · External reference
Protein misfolding and its dual role in neurodegeneration and cancer progression
10.1016/bs.apcsb.2025.10.001 · 2025 · External reference
Protein misfolding and neurodegeneration: mechanisms, implications, and therapeutic strategies
10.1016/bs.apcsb.2025.08.012 · 2025 · External reference
Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated
10.1093/brain/awy146 · 2018 · External reference
A broader view of dementia: multiple co-pathologies are the norm
10.1093/brain/awy153 · 2018 · External reference
Pathological combinations in neurodegenerative disease are heterogeneous and disease-associated
10.1093/brain/awad059 · 2023 · External reference
The pathotome and precision health
10.1093/brain/awad154 · 2023 · External reference
Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry
10.1111/j.1750-3639.2000.tb00269.x · 2000 · External reference
The neuropathology of probable Alzheimer disease and mild cognitive impairment
10.1002/ana.21706 · 2009 · External reference
Pathological alpha-synuclein distribution in subjects with coincident Alzheimer's and Lewy body pathology
10.1007/s00401-015-1526-9 · 2016 · External reference
Alpha-synuclein deposition patterns in Alzheimer's disease: association with cortical amyloid beta and variable tau load
10.1007/s00401-025-02952-w · 2025 · External reference
Lewy body pathology in Alzheimer's disease: a clinicopathological prospective study
10.1111/ane.13028 · 2019 · External reference
Prodromal clinical manifestations of neuropathologically confirmed Lewy body disease
10.1016/j.neurobiolaging.2008.09.017 · 2010 · External reference
Clinical features of Alzheimer disease with and without Lewy bodies
2015 · External reference
The medial temporal lobe in dementia with Lewy bodies: a comparative study with Alzheimer's disease
10.1002/ana.410430117 · 1998 · External reference
Deposition of beta-amyloid subtypes 40 and 42 differentiates dementia with Lewy bodies from Alzheimer disease
10.1001/archneur.56.9.1111 · 1999 · External reference
Lewy body pathology in familial Alzheimer disease: evidence for disease- and mutation-specific pathologic phenotype
10.1001/archneur.63.3.370 · 2006 · External reference
APOE epsilon4 increases risk for dementia in pure synucleinopathies
2013 · External reference
Cognitive and pathological influences of tau pathology in Lewy body disorders
10.1002/ana.25392 · 2019 · External reference
Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred
10.1007/s00401-002-0563-3 · 2002 · External reference
Advances in the genetics and pathology of Lewy body dementia
10.1016/s1474-4422(25)00363-1 · 2025 · External reference
Clinical and diagnostic implications of Alzheimer's disease copathology in Lewy body disease
10.1093/brain/awae203 · 2024 · External reference
Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis
10.1016/s1474-4422(16)30291-5 · 2017 · External reference
Amyloid-beta (Abeta) plaques promote seeding and spreading of alpha-synuclein and tau in a mouse model of Lewy body disorders with Abeta pathology
10.1016/j.neuron.2019.10.010 · 2020 · External reference
Amyloid-beta modulates the phase separation and aggregation of alpha-synuclein
10.1073/pnas.2501987122 · 2025 · External reference
Abeta42 promotes the aggregation of alpha-synuclein splice isoforms via heterogeneous nucleation
10.1002/1873-3468.70118 · 2025 · External reference
Synergistic interactions between abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline
10.1523/jneurosci.0490-10.2010 · 2010 · External reference
Alpha-synuclein modulates Tau spreading in mouse brains
10.1084/jem.20192193 · 2021 · External reference
Autophagy and neurodegeneration: pathogenic mechanisms and therapeutic opportunities
10.1016/j.neuron.2017.01.022 · 2017 · External reference
Effect and mechanism of rapamycin on cognitive deficits in animal models of Alzheimer's disease: a systematic review and meta-analysis of preclinical studies
10.3233/jad-231249 · 2024 · External reference
mTOR signaling networks: mechanistic insights and translational frontiers in disease therapeutics
10.1038/s41392-025-02493-4 · 2025 · External reference
Dysregulated mTOR signaling in Alzheimer's disease: linking pathogenic mechanisms to emerging therapeutic strategies
10.1177/13872877251400667 · 2026 · External reference
Spermidine as an epigenetic regulator of autophagy in neurodegenerative disorders
10.1016/j.ejphar.2024.176823 · 2024 · External reference
The coming of age of chaperone-mediated autophagy
10.1038/s41580-018-0001-6 · 2018 · External reference
Late-stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1 mouse model of ALS
10.1111/j.1471-4159.2008.05595.x · 2008 · External reference
Amplifying the heat shock response ameliorates ALS and FTD pathology in mouse and human models
10.1007/s12035-023-03509-2 · 2023 · External reference
Small molecule-mediated therapeutic approaches to target tau and Alzheimer's disease
10.1016/bs.apcsb.2024.11.010 · 2025 · External reference
Alzheimer drug Lecanemab gains traditional FDA approval
2023 · External reference
Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial
10.1001/jama.2023.13239 · 2023 · External reference
Donanemab for Alzheimer disease-who benefits and who is harmed?
10.1001/jama.2023.11704 · 2023 · External reference
Lecanemab in early Alzheimer's disease
10.1056/nejmoa2212948 · 2023 · External reference
Trial of Prasinezumab in early-stage Parkinson's disease
10.1056/nejmoa2202867 · 2022 · External reference
Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease
10.1038/s41591-024-02886-y · 2024 · External reference
Sustained effect of prasinezumab on Parkinson's disease motor progression in the open-label extension of the PASADENA trial
10.1038/s41591-024-03270-6 · 2024 · External reference
The neuropsychiatry of Parkinson's disease: advances and challenges
10.1016/s1474-4422(21)00330-6 · 2022 · External reference
Autophagy in human diseases
10.1056/nejmra2022774 · 2020 · External reference
A critical review on neurodegenerative biomarker diagnostics: where is the field heading to?
10.1007/s00216-025-06061-1 · 2025 · External reference
